---
title: "ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236678197.md"
description: "ENWEI PHARMACEUTICAL released its 2024 annual report, with operating revenue of 812 million yuan, a year-on-year increase of 3.43%; net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%; net profit excluding non-recurring gains and losses of 34.7296 million yuan, a year-on-year decrease of 52.80%; basic earnings per share of 0.3728 yuan/share. The company plans to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares"
datetime: "2025-04-20T09:14:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236678197.md)
  - [en](https://longbridge.com/en/news/236678197.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236678197.md)
---

# ENWEI PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 37.4975 million yuan, a year-on-year decrease of 56.56%

According to the Zhitong Finance APP, ENWEI PHARMACEUTICAL (301331.SZ) released its annual report for 2024, reporting an operating income of 812 million yuan for the year, a year-on-year increase of 3.43%; the net profit attributable to shareholders of the listed company was 37.4975 million yuan, a year-on-year decrease of 56.56%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 34.7296 million yuan, a year-on-year decrease of 52.80%; the basic earnings per share were 0.3728 yuan/share. It is proposed to distribute a cash dividend of 1.80 yuan (including tax) for every 10 shares

### Related Stocks

- [301331.CN](https://longbridge.com/en/quote/301331.CN.md)

## Related News & Research

- [Citadel’s purchase of Situational’s stocks at discount is already paying off](https://longbridge.com/en/news/294948608.md)
- [Desert Control subscription rights trading ends as rights issue deadline nears](https://longbridge.com/en/news/294914623.md)
- [Groupe Bruxelles Lambert (ENXTBR:GBLB) Looks Cheap On Half Year Earnings Progress](https://longbridge.com/en/news/294783033.md)
- [Selvaag Bolig IFRS Q2 FY26 EBITDA adjusted for financial expenses rises to NOK 255 million; revenue climbs to NOK 1.45 billion](https://longbridge.com/en/news/295056761.md)
- [01:19 ETHexagon Composites ASA: Second quarter and half year 2026](https://longbridge.com/en/news/295057828.md)